Navigation Links
Cancer Prevention Pharmaceuticals, Inc. Announces Appointment of Jon S. Saxe to its Board of Directors

TUCSON, Ariz., July 23, 2015 /PRNewswire/ -- Cancer Prevention Pharmaceuticals, Inc. (CPP) today announced that Jon S. Saxe has joined its Board of Directors.

Saxe brings to CPP many years of experience from the biotechnology, pharmaceutical and venture capital industries.  He has served as a director of more than 25 companies and currently is a director of several biotechnology companies, including: SciClone Pharmaceuticals (NASDAQ: SCLN), where he is chairman; DURECT Corporation (NASDAQ: DRRX); as well as a number of private companies. He was president of PDL BioPharma (formerly Protein Design Labs), and also was president and CEO of Synergen, a biotechnology company purchased by Amgen.

Prior to his work at biotech companies Saxe was vice president of licensing and corporate development and head of patent law for Hoffmann-LaRoche Inc., where he worked for 29 years.  

Saxe received a B.S.ChE from Carnegie Mellon University, a J.D. from George Washington University School of Law, and a LL.M. from New York University School of Law.

"We are honored and excited to have Jon Saxe join our board," said Jeff Jacob, chairman of CPP's Board of Directors.  "His broad knowledge of the industry and years of experience both as an executive and in corporate governance will serve CPP well as it continues to grow in the coming years.  The other members of the board and I are very much looking forward to working with Jon."

About Cancer Prevention Pharmaceuticals, Inc. (CPP)

CPP is developing therapeutics that reduce the risk of cancer.  CPP's approach has been used with great success in other disease categories such as cardiovascular, neurovascular and infectious disease.  Agents that target pre-disease states have helped reduce death rates from these conditions by 50%-70% over the past 30 years.  Just as these other prevention therapies represent the largest-selling drug classes on the market today, CPP believes there is even more potential for therapies that reduce the risk of cancer.  CPP is sponsoring a large Phase III trial in colon cancer survivors and a Phase III trial for Familial Adenomatous Polyposis (FAP), an orphan disease that causes hundreds-to-thousands of colon polyps and has a 100% risk of colon cancer unless treated by surgical removal of the colon/rectum.  CPP is also working collaboratively with non-profit groups to support clinical trials in the childhood cancer neuroblastoma, for the prevention of relapse.  Additional information on CPP is available at


SOURCE Cancer Prevention Pharmaceuticals, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual Meeting
2. ASCO 2013: Boehringer Ingelheim to Present Data Across Multiple Cancers, Including Different Treatment Settings for Advanced NSCLC
3. AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
4. RuiYi and Genor BioPharma Collaborate on Development in China of RYI-008, a Novel Therapeutic for Autoimmune Diseases and Cancer
5. RuiYi et Genor BioPharma collaborent au développement du RYI-008 en Chine, un nouveau traitement contre les maladies auto-immunes et le cancer
6. Cancer Vaccine Partnering Terms and Agreements
7. MultiCell Technologies Files U.S. Patent Application for Targeted Delivery of Noncoding Micro RNAs for the Treatment of Liver Cancer
8. RAD Technology Medical Systems Delivers Innovative Time Saving Modular Construction At New Swedish Cancer Institute Facility
9. National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill
10. Puerto Ricos Caribbean Imaging and Radiation Therapy Center Orders Elektas New Versa HD System for Treatment of Cancer Patients
11. New Data Validates CyberKnife SBRT for Prostate Cancer Treatment
Post Your Comments:
(Date:12/13/2018)... ... ... It’s time to start thinking about New Year’s resolutions. Women’s Excellence ... to maintain a healthy lifestyle. Women’s Excellence is committed to helping patients reach ... to document goals, discuss expected results, and begin a diet regimen and exercise regimen. ...
(Date:12/13/2018)... Calif. (PRWEB) , ... December 13, 2018 , ... ... for Accessibility grant from Microsoft to help further our efforts in improving ... the familiar technology of mobile devices in combination with power of artificial intelligence ...
(Date:12/13/2018)... ... December 13, 2018 , ... ... + Clinical Leadership 2019 Conference, May 2 to 4 at the Swissotel in ... with sessions and panels discussing the best use of artificial intelligence, telehealth, data ...
Breaking Medicine Technology:
(Date:12/13/2018)... Ga. (PRWEB) , ... December 13, 2018 , ... ... newest partnership with the Major Arena Soccer League becoming the official turf ... most advanced indoor artificial turf system available. The indoor product FastGrass™ allows athletes ...
(Date:12/13/2018)... WASHINGTON (PRWEB) , ... December 13, 2018 , ... ... Brad Swelstad, M.D., to the practice’s Virginia medical team, seeing patients ... Woodbridge, VA with a full range of state-of-the-art diagnostic and treatment options for ...
(Date:12/13/2018)... ... December 13, 2018 , ... Women’s Excellence recently implemented a new online ... their questions answered. Women’s Excellence is proud to announce that the chat service ... be available during evening hours. , “This is the second time I have used ...
(Date:12/13/2018)... ... , ... Researchers at the Icahn School of Medicine at Mount Sinai have ... of proliferation ever observed in adult human beta cells—the cells in the pancreas that ... the body’s ability to produce insulin. , The finding involved one drug that inhibits ...
(Date:12/13/2018)... ... December 13, 2018 , ... ... Penn Hospital, and Westfield Memorial Hospital, all part of Allegheny Health Network (AHN), ... Information Management Executives (CHIME). , Most Wired® is the industry-leading survey on IT ...
Breaking Medicine News(10 mins):